NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
Clinical Trials
9 trialsNCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT05498792 2025-04-04
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT03526185 2022-07-25
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
Yale University
Phase EARLY_PHASE1 Terminated
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn